Bruun Jens Meldgaard
Ugeskr Laeger. 2016 Oct 31;178(44).
Obesity is a chronic condition, which is why pharmacotherapy can be considered, if lifestyle modification (hypocaloric diet/exercise) does not result in a weight loss of at least 5%. Pharmacotherapy is indicated, if an individual has a BMI > 30 kg/m or a BMI > 27 kg/m and concomitant disease (e.g. Type 2 diabetes), and can be liraglutide (3 mg) or orlistat (120 mg/60 mg). Choice of treatment must be based on patient preferences and clinical situation, side effects, contraindications and financial considerations. Weight loss of < 5% (about 4-5 kg) after 12 weeks should lead to cessation of the treatment.
肥胖是一种慢性疾病，这就是为什么如果生活方式改变（低热量饮食/运动）未能使体重减轻至少5%，就可以考虑药物治疗。如果个体的体重指数（BMI）>30kg/m²或BMI>27kg/m²且伴有其他疾病（如2型糖尿病），则适合进行药物治疗，药物可以是利拉鲁肽（3mg）或奥利司他（120mg/60mg）。治疗方案的选择必须基于患者的偏好、临床情况、副作用、禁忌症以及经济因素。12周后体重减轻不足5%（约4 - 5千克），则应停止治疗。
